An interventional study of EXPLORER in Neuromuscular Disorders and Neurodevelopmental Disorders, sponsored by MarsiBionics. Completed at 6 sites in Spain. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Neuromuscular Diseases with a site in Spain — 5 open to participants now, 10 under way, 3 of them phase 3. Neuromuscular Diseases · Spain.
Among the 35 studies in Neuromuscular Diseases with a site in Spain, this one is the 24th largest by enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 with no phase, and was the 28th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →5 of the 35 studies in Neuromuscular Diseases with a site in Spain are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Spain, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
AstraZeneca · Sites in Spain, United States, Canada and 7 more countries
Ages 18–70
Vertex Pharmaceuticals Incorporated · Sites in Spain, United States, Australia and 5 more countries
Ages 18+
MarsiBionics · Sites in Spain, Mexico
Ages 2–17 · Healthy volunteers
MarsiBionics · Sites in Spain
Ages 18–85 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 9
First in 2012; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 30 across 204 interventional studies indexed under Neuromuscular Diseases.
Median enrollment 55 across the 30 interventional studies, 48 across the 5 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 35 have an industry lead sponsor. The 10 most frequent:
MarsiBionics is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
MarsiBionics has 6 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuromuscular Diseases with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Neuromuscular Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. EXPLORER is a robotic gait exoskeleton designed to rehabilitate children with motor disabilities in home and outdoor environments.
The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.
Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. Robotic devices are a useful tool in the rehabilitation of these children, but most of them are designed to be used in the clinical setting. EXPLORER is a robotic device designed to assist gait in children with motor disability in their homes and the community. The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.
An initial session will be conducted in the participant's natural environment, during which the researchers will instruct the primary caregivers on the use of the device. Subsequently, the device will be left for a two-month period for use in the natural settings deemed appropriate by the family.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
Device: EXPLORER
Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
Serious Adverse Events
occurrence of any serious adverse event to the participant or the caregiver
Time frame: through study completion, along 2 weeks
Falls prevalence
Number of falling events occurred from the participant or caregiver
Time frame: through study completion, along 2 weeks
Skin integrity
Occurrence of any injury of the skin in the areas of contact and produced by the use of the device
Time frame: through study completion, along 2 weeks
Pain (Visual Analogic Scale)
pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"
Time frame: through study completion, along 2 weeks
Donning and doffing time
Time to don and doff the device to each participant
Time frame: through study completion, along 2 weeks
Device usage time
Time using the device
Time frame: through study completion, along 2 weeks
Number of steps
number of steps with the device
Time frame: through study completion, along 2 weeks
Usage modes
two different usage modes (active and automatic).
Time frame: through study completion, along 2 weeks
Speed
speed achieved with the device (steps per minute)
Time frame: through study completion, along 2 weeks
Device accessibility
Environments where the device has been used and level of accessibility in each environment measured with a 5 points Likert scale (0 not accessible - 5 very accessible)
Time frame: through study completion, along 2 weeks
Range of motion
Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.
Time frame: Before starting the intervention (S1) and after completing the two weeks of use
Participation
Measured with the Child and Adolescent Scale of Participation. 20 ordinal scaled items across 4 subsections. Maximum total score is 80 (20 items x 4) and the minimum total score is 20 (20 items x 1)
Time frame: Before starting the intervention (S1) and after completing the two weeks of use
QUEST
Using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale
Time frame: at the end of the intervention
Ran from Mar 2025 to primary completion in Aug 2026, 17 months.
Of 84 interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 17 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Apr 2025 → Aug 2026 and completion Dec 2025 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MarsiBionics